Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200881 | 0.79 | ADORA2A (0.36) | ADORA2AADORA2BCYP1A2BTK | |
| SCHEMBL31190661 | 0.76 | GAA (0.32) | GAAGRIA1CACNG8 | |
| SCHEMBL1848211 | 0.76 | GAA (0.32) | GAAGRIA1CACNG8 | |
| SCHEMBL27192096 | 0.76 | ADORA2A (0.34) | ADORA2AADORA2BCYP1A2BTK | |
| SCHEMBL17028038 | 0.76 | GAA (0.56) | GAABTKGRIA1CACNG8 | |
| SCHEMBL25112233 | 0.72 | BTK (0.31) | BTK | |
| SCHEMBL2614375 | 0.72 | GAA (0.61) | CYP1A2GAA | |
| SCHEMBL19780200 | 0.72 | MAP2K1 (0.37) | ADORA2AADORA2B | |
| SCHEMBL25112226 | 0.71 | HCAR2 (0.34) | ADORA2AADORA2BCYP1A2 | |
| SCHEMBL13122187 | 0.69 | MAP2K4 (0.34) | ADORA2AADORA2BCYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011141756-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | ADORA2A 991/4885ADORA2B 2318/4885CYP1A2 1046/4885 |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ADORA2A 991/4885ADORA2B 2318/4885CYP1A2 1046/4885 |
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | LRRK2, PARK7, GRK3 | ADORA2A 1701/4885ADORA2B 1234/4885CYP1A2 3622/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | ADORA2A 991/4885ADORA2B 2318/4885CYP1A2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.